stockrow
Saturday 7 November 2026
Export MLTX’s income statement to Excel — free account
MoonLake Immunotherapeutics
MLTX Healthcare Biotechnology
- EPS
- +3.45%
- Free cash flow
- −1.89%
- Total debt
- +35.6%
Quarter to June 2026, against a year earlier
11.49
0.69
+6.39%
Follow MLTX
Alert me
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
| (67.08%) | (77.13%) | (59.99%) | (53.51%) |
+8 more TTM periods Free account |
|
| (51.00%) | (56.40%) | (50.38%) | (45.14%) | ||
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | |
Return on Tangible Assets |
(50.21%) | (73.23%) | (60.33%) | (57.91%) | |
Average Days of Receivables |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
(3.05) | (3.14) | (3.04) | (2.93) | |
Free Cash Flow |
(225.18) | (224.15) | (196.04) | (185.90) | |
Capital Expenditures |
— | — | (0.03) | (0.21) | |
| Other line items | |||||
Cash ROIC |
(21.15%) | (31.53%) | (25.38%) | (24.94%) | |
Accounts Receivable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Interest Coverage |
(26.58) | (28.15) | (33.78) | (43.56) | |
Operating CF/Net income |
0.85 | 0.87 | 0.86 | 0.88 | |
Depreciation/Fixed assets |
6.65 | 5.80 | 4.53 | 3.58 | |
Capex/Depreciation |
0.00 | 0.00 | (0.01) | (0.09) | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(3.05) | (3.14) | (3.04) | (2.93) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
— | — | 0.00 | 0.00 |
Columns are period end dates